CYX Calyx Ventures Inc

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is pleased to announce that it has
been recognized as a TSX Venture 50(R) company in 2013. The 2013 TSX Venture
50(R) includes the top 10 companies in 5 major industry sectors that have been
identified as leaders in providing shareholder value on Canada's junior stock
exchange.


"We couldn't be more pleased to be included in the 2013 TSX Venture 50(R) as a
member of the Technology and Life Sciences sector," said Calyx President and CEO
Hugh Notman. "This honour continues to build momentum for Calyx, as we continue
our efforts to promote Resonance(TM) carinata, a non-food oilseed crop for use
in biofuels, through our majority-owned subsidiary Agrisoma Biosciences Inc.
It's not only a recognition for our company-it's also a nod to our shareholders
for their vision."


The TSX Venture 50(R) are the top 10 companies listed on the TSX Venture
Exchange, in each of five major industry sectors - mining, oil & gas, technology
& life sciences, diversified industries and clean technology - based on a
ranking formula with equal weighting given to return on investment, market cap
growth, trading volume and analyst coverage. All data was as of December 31,
2012.


TSX Venture 50(R) is a trade-mark of TSX Inc. and is used under license.

About Calyx

Calyx Bio-Ventures Inc. trades on the TSX Venture Exchange under the symbol
"CYX" and owns a majority position in Agrisoma Biosciences Inc. Agrisoma is an
agricultural biotechnology company that uses a proprietary Engineered Trait Loci
(ETL) technology licensed from Calyx to commercialize a suite of
industry-leading oil quality and crop improvement traits for use in energy
feedstock crops. Agrisoma is currently commercializing Resonance(TM) carinata, a
non-food oilseed crop that is well suited for cultivation on semi-arid lands.
For further information about Calyx, its technology, collaborations and
partnerships, please visit www.calyxbio.com. For more information about
Agrisoma, visit www.agrisoma.com.


This press release shall not constitute an offer to sell, nor the solicitation
of an offer to buy, any securities in the United States, nor shall there be any
sale of securities mentioned in this press release in any state in the United
States in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
W. Hugh Notman
President & CEO
604-689-2495
hnotman@calyxbio.com


Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com

Calyx Ventures (TSXV:CYX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Calyx Ventures (TSXV:CYX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024